Researchers from the University of Gothenburg, Sweden, have developed a more accurate method of testing anti-cancer drugs, which allows to assess in advance whether a particular drug is effective.
"Cancer patients prescribed drugs that do not help or have side effects. But we have shown that the method can be used at the stage of drug development to determine which groups of patients it fit, "- said Berglind Eynarsdottir USC researcher Cancer Center.
The method is based on tumor biopsies during surgery - tissue samples are processed, and implanted under the skin of a few mice.
In his research studies Eynarsdottir tumor growth in animal models, and check how they respond to various cancer treatments . The experiments take from several weeks to several months, depending on the rate of tumor growth.
"This method has not been used in the Swedish health care, but we have decided to carry out experiments to show that it works and can be used in the future if necessary," - said Boris O. Eynarsdottir.
According Eynarsdottir, the advantage lies in the fact that one and the same drug tested on mice implanted with tumor tissues of different patients. In an additional study, 33 people responded to the anti-cancer agent Karonudib, who recently designed the Karolinska Institute in Sweden.
Experiments have shown that two thirds of the samples of the patients responded to treatment. The question was what they had in common - like DNA metabolism, protein expression, or other factor. Such knowledge will better predict when a patient will be able to destroy cancer cells.
"No matter what mutations are found in the tissues. Tumors can become resistant to treatment. In some of the high expression of a protein that helps cells repel medicine, and we have found a potential mechanism of resistance. You can use the method to determine which anti-cancer medicine is better suited to the patient or a particular subgroup of patients, "- adds Eynarsdottir.